Next-generation triple-action anti-IgE antibody PHB-050 for IgE-mediated diseases (food allergy, allergic asthma, atopic dermatitis); Phase 1 underway with H2 2026 readout; cumulative $95M Series A
No detailed funding rounds available.
Total known funding: